Dexmedetomidine: a real-world safety analysis based on FDA adverse event reporting system database

Area of Science:

• Pharmacovigilance
• Clinical Pharmacology
• Drug Safety

Background:

• Dexmedetomidine is widely used for sedation and anesthesia.
• Understanding its comprehensive safety profile is crucial for clinical application.
• The FDA Adverse Event Reporting System (FAERS) database offers a valuable resource for post-market drug surveillance.

Purpose of the Study:

• To analyze the safety profile of Dexmedetomidine using FAERS data.
• To identify both known and previously unreported adverse events associated with Dexmedetomidine.
• To provide evidence-based guidance for the safe clinical use of Dexmedetomidine.

Main Methods:

• Utilized data from the FAERS database (Q1 2004 - Q3 2023).
• Employed statistical methods including Reporting Odds Ratio (ROR), Proportional Reporting Ratio (PRR), and Bayesian Confidence Propagation Neural Network (BCPNN).
• Analyzed 1910 reports, identifying 892 preferred terms, including 52 new terms.

Main Results:

• Common adverse events included bradycardia, cardiac arrest, hypotension, and agitation.
• Cardiac disorders emerged as the most frequently reported system organ class with high signal intensity.
• Identified novel adverse events with high signal intensity, such as acute motor axonal neuropathy and floppy iris syndrome.

Conclusions:

• This pharmacovigilance study successfully identified known and new adverse events of Dexmedetomidine.
• The findings highlight the importance of monitoring for specific adverse events, including those not listed in the drug insert.
• This research provides critical insights to enhance clinical vigilance and mitigate risks associated with Dexmedetomidine therapy.